FDA has granted Breakthrough Therapy Designation to Epkinly (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
